Volume 2 Issue 1
Severe Uncontrolled Allergic Asthma: The Use of Omalizumab in Routine Care
Our improved theoretical understanding of IgE-mediated immediate-type allergic diseases has led to an important step forward in treating patients suffering from severe uncontrolled asthma – a major global health problem. In 2005, omalizumab (Xolair®), a humanized anti-IgE antibody received approval for the treatment of (moderate-to-) severe persistent asthma. Omalizumab interferes with the allergic cascade by binding free serum IgE, blocking the interaction of IgE with basophils or mast cells.
Dust Allergens within Rural Northern Rocky Mountain Residences
Emily Weiler BS, Erin Semmens PhD, Curtis Noonan PhD, Carol Cady MD, and Tony Ward PhD*
To date, few studies have characterized allergens within residences located in rural areas of the northern Rocky Mountain region. In this study, we collected dust samples from 57 homes located throughout western Montana and northern Idaho. Dust samples were collected and later analyzed for dust mite allergens Der f 1 and Der p 1, Group 2 mite allergens (Der p 2 and Der f 2), domestic feline (Fel d 1), and canine (Can f 1). Indoor temperature and humidity levels were also measured during the sampling program, as were basic characteristics of each home.
Role of Neuroinflammation in the Pathogenesis of Painful Neuropathy in Type 2 Diabetes
HaeJee Yoon, Vikram Thakur and Munmun Chattopadhyay*
Painful diabetic neuropathy (PDN) is an important complication of diabetes. The Zucker diabetic fatty (ZDF) rat is an established model for Type 2 diabetes (T2D). To investigate the potential role of inflammation in the pathogenesis of painful neuropathy in this model, we used a microarray to study cytokine/chemokine expression in the spinal cord dorsal horn and correlated changes in expression of TRPV1 channel which is related to thermal pain. After 6 weeks of hyperglycemia, significant changes were observed in thermal latency and in mechanical pain threshold in ZDF animals compared to their lean controls.